Cannabinoid Type 2 Receptor as a Target for Chronic - Pain

被引：50

作者：

Beltramo, Massimiliano ^{[1
]}

机构：

[1] Schering Plough Res Inst, I-20132 Milan, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 01期

关键词：

Analgesia; agonist; neuropathic pain; signalling pathways; ACTIVATED PROTEIN-KINASE; DORSAL-HORN NEURONS; CB2; RECEPTOR; IN-VITRO; NUCLEAR FACTOR; PHARMACOLOGICAL CHARACTERIZATION; SELECTIVE ACTIVATION; DOWN-REGULATION; MESSENGER-RNA; AGONIST;

D O I：

10.2174/138955709787001785

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Availability of selective pharmacological tools enabled a great advance of our knowledge of cannabinoid receptor 2 ( CB2) role in pathophysiology. In particular CB2 emerged as an interesting target for chronic pain treatment as demonstrated by several studies on inflammatory and neuropathic preclinal pain models. The mechanisms at the basis of CB2-mediated analgesia are still controversial but data are pointing out in two main directions: an effect on inflammatory cells and/or an action on nociceptors and spinal cord relay centers. In this review will be described the second messenger pathways activated by CB2 agonists, the data underpinning the analgesic profile of CB2 selective agonists and the mechanisms invoked to explain their analgesic action. Finally the ongoing clinical trials and the potential issues for the development of a CB2 agonist drug will be examined.

引用

收藏

页码：11 / 25

页数：15

相关论文

共 96 条

[71]

PAI MV, 2007, SOC NEUR M SAN DIEG

[72] Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation [J].

Palazuelos, Javier ;

Aguado, Tania ;

Egia, Ainara ;

Mechoulam, Raphael ;

Guzman, Manuel ;

Galve-Roperh, Ismael .

FASEB JOURNAL, 2006, 20 (13) :2405-+

[73] Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors [J].

Quartilho, A ;

Mata, HP ;

Ibrahim, MM ;

Vanderah, TW ;

Porreca, F ;

Makriyannis, A ;

Malan, TP .

ANESTHESIOLOGY, 2003, 99 (04) :955-960

[74] SR141716A, A POTENT AND SELECTIVE ANTAGONIST OF THE BRAIN CANNABINOID RECEPTOR [J].

RINALDICARMONA, M ;

BARTH, F ;

HEAULME, M ;

SHIRE, D ;

CALANDRA, B ;

CONGY, C ;

MARTINEZ, S ;

MARUANI, J ;

NELIAT, G ;

CAPUT, D ;

FERRARA, P ;

SOUBRIE, P ;

BRELIERE, JC ;

LEFUR, G .

FEBS LETTERS, 1994, 350 (2-3) :240-244

[75] Agonist inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 [J].

Ross, RA ;

Brockie, HC ;

Stevenson, LA ;

Murphy, VL ;

Templeton, F ;

Makriyannis, A ;

Pertwee, RG .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (03) :665-672

[76] Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats [J].

Sagar, DR ;

Kelly, S ;

Millns, PJ ;

O'Shaughnessey, CT ;

Kendall, DA ;

Chapman, V .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2005, 22 (02) :371-379

[77]

SAIN NMH, 2005, SOC NEUR M WASH DC

[78] Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord [J].

Salio, C ;

Fischer, J ;

Franzoni, MF ;

Conrath, M .

NEUROSCIENCE, 2002, 110 (04) :755-764

[79] Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3 cells.: Involvement in Raf-1 stimulation and NGF induction [J].

Sánchez, MG ;

Ruiz-Llorente, L ;

Sánchez, AM ;

Díaz-Laviada, I .

CELLULAR SIGNALLING, 2003, 15 (09) :851-859

[80] Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system [J].

Schatz, AR ;

Lee, M ;

Condie, RB ;

Pulaski, JT ;

Kaminski, NE .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 142 (02) :278-287

← 1 2 3 4 5 6 7 8 9 10 →